PDCD1 and cancer: The expression of Siglec-15 and PD-L1 has been reported to be mutually exclusive in several types of cancer, suggesting that targeting Siglec-15 may provide an alternative therapeutic strategy for cancers unresponsive to anti-PD-L1/PD-1 immunotherapy [64, 65].